ArticleLeukemia2024

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.

Catherine Thieblemont et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.